201 Therapeutics raises CHF 150,000

201 Therapeutics, which stems from the University of Basel, is researching liver cancer drugs using organoids derived from patient tumours. The CHF 150,000 InnoBooster from Gebert Rüf Stiftung funds in vivo validation of its most advanced molecule series.

Announced on
Round
Grant
Amount
CHF 150,000
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic